BALCAO · SERVICES-MANAGEMENT CONSULTING SERVICES · SMALL CAP
Pharma-bio Serv, Inc. PBSV
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$9.0M
▼ 5.3% vs FY2024
EPS · FY25
$-0.00
Dividend / sh · FY25
—
Payout · FY25
-1712%
ROE · FY25
-0.8%
Net margin · FY25
-1.1%
Dividend coverage
1.2×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 9.0M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 1 cents on every revenue dollar this year.
Per share
USD -0.00
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 1.2 times — the rest stayed in the company.
Profitability
-0.8%
Return on equity, FY2025
ROE
Operating margin-7.1%
Net margin-1.1%
Return on assets-0.7%
Each USD of equity lost 1 cents this year.
Returned to shareholders
USD 1.8M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 1.7M
Net buybacksUSD 31,443.00
Share of profit-1743.3%
Consecutive raises—
USD 1.7M in dividends and USD 31,443.00 in buybacks went back to shareholders in a year without profit.
Growth
−16.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−22.6%
−16.0%
−9.1%
−1.5%
Returned to shareholders
−20.8%
+0.3%
+26.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years−0.4%
Change, 10 years−0.5%
The share count shrank 0% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 13.7M
total assets, end of FY2025
Total assetsUSD 13.7M
EquityUSD 11.9M
CashUSD 3.4M
Current ratio7.70×
Equity funds 87% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
EBITDA $B
·
·
·
0.0
−0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
−0.00
−0.03
0.06
·
·
0.09
0.09
·
−0.06
−0.01
0.07
0.10
0.21
0.20
0.14
0.02
Dividend / sh $
·
·
·
·
·
·
0.07
·
·
·
·
·
·
·
·
·
Payout %
−1712
−221
132
342
−83
84
0
·
·
·
·
·
·
·
·
·
ROE %
−0.8
−5.2
8.0
5.7
−10.0
9.5
10.2
6.2
−6.6
−1.2
7.7
12.5
31.7
44.4
47.5
7.3
Shares out B
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
61 of 61
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed